Pure Biologics Spólka Akcyjna reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was PLN 6.42 million compared to PLN 4.28 million a year ago. Basic loss per share from continuing operations was PLN 2.85. Diluted loss per share from continuing operations was PLN 2.85.
For the nine months, net loss was PLN 18.44 million compared to PLN 11.07 million a year ago. Basic loss per share from continuing operations was PLN 8.18 compared to PLN 5.01 a year ago. Diluted loss per share from continuing operations was PLN 8.18.